H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arbutus Biopharma (ABUS – Research Report) today and set a price target of $6.00. The company’s shares closed yesterday at $2.20.
Arce covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, CymaBay Therapeutics, and Cidara Therapeutics. According to TipRanks, Arce has an average return of 10.7% and a 40.72% success rate on recommended stocks.
Arbutus Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $5.00, which is a 127.27% upside from current levels. In a report released yesterday, Chardan Capital also maintained a Buy rating on the stock with a $4.00 price target.
See today’s best-performing stocks on TipRanks >>
ABUS market cap is currently $368.6M and has a P/E ratio of -4.76.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
Read More on ABUS:
- Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical Trial with AB-101; Cash Runway Extended
- Arbutus to Participate in Two Upcoming Investor Conferences
- Arbutus Biopharma reports Q2 EPS (10c), consensus (11c)
- Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update
- Is ABUS a Buy, Before Earnings?
